Latest Articles and Analysis

Q1 2026 Watch: HCV/HIV co-infection treatment access under evolving federal and state policies.

Florida ADAP cuts eligibility from 400% to 130% FPL, threatening 16,000 PLWHA.

340B program drifted from patient benefit; federal reform needed for transparency and accountability.

Enhanced ACA subsidies expired Jan 1; Senate framework proposes two-year extension with restrictions.

CANN marks 30th anniversary with expanded partnerships and cross-condition advocacy evolution.

Lupus Colorado partnership with CANN demonstrates how disease-specific and multi-condition advocates amplify healthcare policy impact.

2025 healthcare crises result from policy choices as ACA subsidies expire, HIV care deteriorates, and state pricing experiments proliferate.

World AIDS Day honors resilience of HIV advocates and communities resisting policy failures and system barriers to care.

Personal narrative on becoming an HIV advocate and the gratitude found in fighting for healthcare access from lived experience.

HIV care system deterioration from administrative obstruction and funding delays presages catastrophic effects of potential budget cuts.

Federal policy changes including Medicaid work requirements and ADAP eligibility restrictions threaten access to HIV medications.

Senate HELP Committee hearing reveals how 340B drug program expansion reflects hospital business strategy rather than patient benefit.

Q4 2025 Watch monitoring HCV treatment access and federal initiatives including Cure Hepatitis C Act.

Clade I mpox emergence reveals structural collapse in U.S. disease surveillance and public health response infrastructure.

Miss Major Griffin-Gracy's legacy demonstrates solidarity's power in building healthcare justice and community leadership.

Government shutdown disrupts grant payments to community health centers and crisis service providers, threatening vulnerable population access.

Deteriorating healthcare infrastructure and provider shortages exacerbate rising rates of sexually transmitted infections.

European price controls demonstrate MFN policy risks: delayed access, treatment rationing, and pharmaceutical innovation collapse.

September government shutdown threatens healthcare systems during November open enrollment, risking coverage loss for 22 million Americans.

Congressional Budget Office confirms 340B program expansion driven by hospital exploitation rather than pharmaceutical price inflation.